Takeda Pharmaceutical Company
Open
$16.72
Prev. Close
$16.72
High
$16.73
Low
$16.72
Market Snapshot
$50.92B
71.9
0.44
$30.18B
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. The firm focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The firm focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The firm operates in Japan, the United States, Europe, and China.
emptyResult
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. The firm focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The firm focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The firm operates in Japan, the United States, Europe, and China.
Recently from Cashu
Eli Lilly Expands Neuroscience Portfolio with Centessa Acquisition, Challenging Takeda’s Position
Eli Lilly's Strategic Expansion in Neuroscience: Implications for the Competitive Landscape Eli Lilly and Company takes a significant step in the neuroscience space with its recent announcement to acq…
Takeda Pharmaceutical Company Invests in Innovative Mental Health Therapies to Address Global Demand
Takeda Pharmaceutical Company Targets Innovations in Mental Health Treatments In a landscape where mental health disorders impact over 970 million individuals globally, Takeda Pharmaceutical Company r…
Helus Pharma's NSAs: Pioneering Innovations in Mental Health Therapeutics Market Growth
Innovative Serotonergic Therapies on the Rise in Mental Health Treatment Helus Pharma is making significant strides in the booming mental health therapeutics market, which is set to surpass $40 billio…
Takeda's Phase 3 Entyvio win reshapes GI strategy, pending full data and regulatory review
Takeda’s late‑stage win for Entyvio reshapes its gastroenterology strategy Takeda Pharmaceutical is presenting positive Phase 3 results for its biologic Entyvio in a late‑stage clinical study, a devel…